Cargando…
Immunophenotyping of Waldenströms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications
Waldenströms macroglobulinemia (WM) is a subtype of Non-Hodgkin’s lymphoma in which the tumor cell population is markedly heterogeneous, consisting of immunoglobulin-M secreting B-lymphocytes, plasmacytoid lymphocytes and plasma cells. Due to rarity of disease and scarcity of reliable preclinical mo...
Autores principales: | Paulus, Aneel, Chitta, Kasyapa S., Wallace, Paul K., Advani, Pooja P., Akhtar, Sharoon, Kuranz-Blake, Maja, Ailawadhi, Sikander, Chanan-Khan, Asher A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390194/ https://www.ncbi.nlm.nih.gov/pubmed/25853860 http://dx.doi.org/10.1371/journal.pone.0122338 |
Ejemplares similares
-
Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia
por: Chitta, K, et al.
Publicado: (2014) -
Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström Macroglobulinemia
por: Gaudette, Brian T., et al.
Publicado: (2015) -
Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment
por: Paulus, A, et al.
Publicado: (2017) -
Targeted treatment for chronic lymphocytic leukemia
por: Masood, Aisha, et al.
Publicado: (2011) -
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells
por: Paulus, A, et al.
Publicado: (2016)